Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - July 28, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 92     Next >>     Go To Page:

7/20/17 - Dewmar International BMC, Inc. (DEWM) Secures Memorandum of Understanding with Smart Rx Systems for Distribution of Smart PharmAssist
Dewmar International BMC, Inc. announced today that it has entered into an agreement with Smart RX Systems, Inc. to sell and market its Smart PharmAssist Kiosk. Per the agreement, Health& Wellness Research Consortium, a fully owned subsidiary of Dewmar International, sold its Texas- based Dimension Pharmacy in exchange for some cash and limited exc
7/20/17 - HEALTH & SUPPORT
Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at Beverly Hospital, 85 Herrick St., Beverly. Financial counselors are available at Beverly Hospital, 85 Herrick St., Beverly, to assist you in accessing health insurance. Beverly Hospital is offering several American Heart Association CPR courses designed for non
7/20/17 - Innovus Pharma's Partner Luminarie Receives Approval for Zestra for Female Sexual Arousal Disorder as a Medical Device I from Australia's Therapeutic Goods Administration
Innovus Pharmaceuticals, Inc., an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men s and women s health and vitality and respiratory diseases, announced today that i
7/20/17 - NEUROMETRIX, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Unless the context otherwise requires, all references to "we", "us", the "Company", or "NeuroMetrix" in this Quarterly Report on Form 10- Q refer to NeuroMetrix, Inc.. NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, slee
7/20/17 - OncBioMune Acquires Propolis Product Line for German Partner
OncBioMune Pharmaceuticals, Inc., a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce the acquisition of the rights to six Aagaard Propolis products for the Mexican...
7/20/17 - Peer and Recovery Support Group
Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at Beverly Hospital, 85 Herrick St., Beverly. Financial counselors are available at Beverly Hospital, 85 Herrick St., Beverly, to assist you in accessing health insurance. Beverly Hospital is offering several American Heart Association CPR courses designed for non
7/20/17 - Pilot Project Program Under the Drug Supply Chain Security Act; Request for Comments
Under this program, FDA will work with stakeholders to establish one or more pilot projects to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain. FDA will be particularly interested in participation reflecting the diversity of the supply chain, including large and small entities from all
7/20/17 - Technical Reports on Drug Makers Equities TherapeuticsMD, GlaxoSmithKline, Novartis, and Impax Labs
Today's research on DailyStockTracker.com is centered on the following major players in the Drug Manufacturers space: TherapeuticsMD Inc., GlaxoSmithKline PLC, Novartis AG, and Impax Laboratories Inc.. On Wednesday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. climbed 1.71%, ending the day at $5.35. Moreover, shares of Therapeuti
7/20/17 - VANC Pharmaceuticals Announces Non Brokered Private Placement
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.15 per unit for gross proceeds of up to $1,500,000.. This round of financing will serve to build additional inve
7/19/17 - Featured Company News - Valeant Pharma Divests its Skin Care Business, Obagi Medical Products Business
LONDON, UK/ ACCESSWIRE/ July 19, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant Pharmaceuticals International, Inc., following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/? The Company announced on July 17, 2017, that certain
7/19/17 - House Appropriations Committee Issues Report on Agriculture, Rural Development, FDA, Related Agencies Appropriations Bill, 2018 (Part 5 of 6)
The House Appropriations Committee issued a report on legislation in explanation of the accompanying bill making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for fiscal year 2018. The Committee provides an appropriation of $2,759,378,000 in new budget authority for the FDA.
7/19/17 - Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of DermOtic Oil, 0.01% Ear Drops
Perrigo Company plc today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing DermOtic Oil, 0.01% Ear Drops. Annual market sales for DermOtic Oil, 0.01% Ear Drops for the 12 months ending May 2017 were approximately $26 million. Perrigo Company plc
7/18/17 - Allergic Rhinitis Market poised to grow at a CAGR of 7 % till 2023
Major Key Players are Merck, GSK, Sanofi, Cigna, Himalaya, J&J, Chong kun Dang Pharmaceutical Corp., Faes, Farma, Glenmark Pharmaceutical, " Market Research Future PUNE, MAHARASHTRA, INDIA, July 18, 2017/ EINPresswire.com/ Market Highlights Hay fever is another name for allergic rhinitis which is a nose related disease. The sale for anti-allerg
7/18/17 - Pharmaceutical Blister Packaging to Expand 6.5% Annually Through 2021
Blister packs are also widely employed as high visibility containers for over-the-counter tablets, caplets, and capsules sold in quantities of 50 or fewer. These and other trends are presented in Pharmaceutical Packaging Market in the US, 12th Edition, a new study from The Freedonia Group, a Cleveland- based industry research firm. In OTC drug pack
7/17/17 - Daiwa-SSI invests in CVI Pharma's ambition [Vietnam Investment Review (VIR)]
CVI Cosmetic& Pharmaceutical Co., JSC is partnering with Japanese Daiwa-SSI to venture further into the high-tech field with the ambition of becoming one of the top ten drug producers in Vietnam in the next five years. The facility valued at nearly VND300 billion will have an area of 1.1 hectares. For example, in the over-the-counter market, there
7/17/17 - Medication dosage errors increasing across U.S.: Study
Researchers found that the drugs most often associated with unintentional errors included cardiovascular drugs, analgesics and hormones/hormone antagonists like insulin from an analysis of 67,603 cases from the U.S. Poison Control Center between 2000 and 2013.. A third of the cases in the study resulted in hospital admission, and so they are
7/17/17 - Perrigo Announces FDA Final Approval For Its First-To-File Ab Rated Generic Version Of Androgel Topical Gel, 1.62% Packets
Perrigo Company plc today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.' s Androgel Topical Gel, 1.62% packets. Annual market sales for Androgel Topical Gel, 1.62% packets for the 12 months ending May 2017 were approximately $88 m
7/17/17 - Perrigo Announces Settlement Of Generic Version Of Dymista Nasal Spray Patent Litigation
Perrigo Company plc today announced that it has settled the Hatch-Waxman litigation relating to Dymista nasal spray brought by Meda Pharmaceuticals Inc. and Cipla Ltd.. Annual market sales for the twelve months ending May 2017 were $152 million. About Perrigo Perrigo Company plc, a leading global healthcare company, delivers value to its custo
7/17/17 - Perrigo Confirms Patent Challenge For Generic Version Of Soolantra Cream, 1%
Perrigo Company plc today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Soolantra cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a patent litigation suit a
7/17/17 - Self-Administered Drugs Market Poised to Expand at a Robust Pace over 2024
New York, NY 07/17/2017 Self-administered drugs are mainly consumed by patients suffering from chronic diseases like multiple sclerosis, rheumatoid arthritis, diabetes and others. With the increasing number of people suffering from chronic diseases globally the self-administered drugs are expected to witness high demand, mainly among old and
7/14/17 - Intelligent Vending/Retail Systems and the Pharmaceutical Industry in Africa
Magex South Africa and PharmaAfrica24H have entered into a exclusive partnership to bring 24-hour intelligent retail and pharmaceutical vending platforms to Africa.
7/14/17 - Janssen Announces U.S. Fda Approval of Tremfya (Guselkumab) for Treatment of Moderate to Severe Plaque Psoriasis
Johnson and Johnson issued the following news release:. Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration has approved TREMFYA for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. "TREMFYA represents a significant milestone in the treatme
7/14/17 - Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Novartis, a global leader in Immunology& Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis. 1 Data will be presented at a key medical congress in the second half of 2017. 5 year Phase III data are a milestone for
7/14/17 - Rep. Blackburn, Kennedy Hearing Aid Bill Passes House
Marsha Blackburn, R- Tenn., issued the following news release:. Marsha Blackburn, R- Tenn., and Joe Kennedy III, D- Mass., on Wednesday applauded the passage of their bipartisan Over-the-Counter Hearing Aid Act in the U.S. House of Representatives. In addition, the legislation would require the FDA to write regulations ensuring that this new catego
7/14/17 - Reps. Kennedy, Blackburn Hearing Aid Bill Passes House
Joseph P. Kennedy III, D- Mass., issued the following news release:. Congressman Joe Kennedy III and Congressman Marsha Blackburn today applauded the bipartisan passage of their Over-the-Counter Hearing Aid Act in the House of Representatives. In addition, the legislation would require the FDA to write regulations ensuring that this new category of
Articles(s): 1 - 25 of 92     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415